Bioptha Secures €6.5M Seed Funding for Eye Disease Treatment and Trials
Biophta Raises €6.5M in Seed Funding
Bioptha's Seed Funding
Key Highlights:
- Seed Funding: Bioptha, a preclinical biotech company, raised €6.5M in seed funding.
- Investors: Funding led by UI Investissement, Elaia, and GO Capital, with participation from Unither Pharmaceuticals and HTL Biotechnology.
- Product Development: Funds will be used to accelerate first-in-human trials of topical ophthalmic inserts for glaucoma treatment and advance a second program for macular edema.
Bioptha's Target Market
- Target Market: Individuals suffering from eye diseases, particularly glaucoma and macular edema.
- Ophthalmologists and Eye Care Specialists: Medical professionals specializing in the diagnosis and treatment of eye diseases.
- Pharmaceutical Companies: Potential partners for collaboration in drug development and distribution.
What Bioptha Needs to Buy
- Clinical Trial Support: Collaborations with research institutions and clinical trial service providers for conducting first-in-human trials.
- Manufacturing and Supply Chain Solutions: Partnerships with manufacturers for the production of ophthalmic inserts and establishing a reliable supply chain.
- Marketing and Distribution Partnerships: Collaborations with pharmaceutical companies for marketing and distribution of their ophthalmic inserts.